{"product_id":"sabatolimab-mbg453-10mg","title":"Sabatolimab (MBG453) 10mg","description":"\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eDue to the nature of this product being a monoclonal antibody and thus must be manufactured and stored under stringent quality standards, order fulfillment requires additional processing time. Please allow 2–3 weeks for production, plus shipping time, to ensure we deliver a product that meets our quality and purity specifications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"500\" data-start=\"152\"\u003e\u003cstrong data-end=\"176\" data-start=\"152\"\u003eSabatolimab (MBG453)\u003c\/strong\u003e is a \u003cstrong data-end=\"220\" data-start=\"182\"\u003ehumanized IgG4 monoclonal antibody\u003c\/strong\u003e that targets \u003cstrong data-end=\"286\" data-start=\"234\"\u003eTIM-3 (T-cell immunoglobulin and mucin domain-3)\u003c\/strong\u003e—an immune regulatory receptor expressed on multiple immune-cell subsets and also described on \u003cstrong data-end=\"442\" data-start=\"381\"\u003eleukemic blasts \/ leukemic stem-cell–enriched populations\u003c\/strong\u003e in myeloid cancers. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"823\" data-start=\"502\"\u003e\u003cstrong data-end=\"524\" data-start=\"502\"\u003eRegulatory status:\u003c\/strong\u003e Investigational (not FDA\/EMA-approved). It received \u003cstrong data-end=\"595\" data-start=\"577\"\u003eFDA Fast Track\u003c\/strong\u003e for higher-risk MDS in combination with hypomethylating agents (HMAs). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003cbr data-end=\"707\" data-start=\"704\"\u003e\u003cstrong data-end=\"731\" data-start=\"707\"\u003eDevelopment context:\u003c\/strong\u003e Evaluated in the \u003cstrong data-end=\"761\" data-start=\"749\"\u003eSTIMULUS\u003c\/strong\u003e program (MDS\/AML\/CMML). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"828\" data-start=\"825\"\u003e\n\u003ch3 data-end=\"888\" data-start=\"830\"\u003e2) Biological rationale: why TIM-3 in myeloid disease?\u003c\/h3\u003e\n\u003cp data-end=\"958\" data-start=\"889\"\u003eTIM-3 functions as an \u003cstrong data-end=\"942\" data-start=\"911\"\u003e“immuno-myeloid” checkpoint\u003c\/strong\u003e, implicated in:\u003c\/p\u003e\n\u003cul data-end=\"1200\" data-start=\"959\"\u003e\n\u003cli data-end=\"1031\" data-start=\"959\"\u003e\n\u003cp data-end=\"1031\" data-start=\"961\"\u003e\u003cstrong data-end=\"1024\" data-start=\"961\"\u003eT-cell and innate immune suppression\/exhaustion-like states\u003c\/strong\u003e, and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1200\" data-start=\"1032\"\u003e\n\u003cp data-end=\"1200\" data-start=\"1034\"\u003edisease biology in myeloid malignancies where the microenvironment and dysfunctional immunity contribute to persistence\/relapse. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1489\" data-start=\"1202\"\u003eThis created a rationale for \u003cstrong data-end=\"1266\" data-start=\"1231\"\u003ecombining sabatolimab with HMAs\u003c\/strong\u003e (azacitidine\/decitabine): HMAs can modulate tumor\/immune gene programs, while TIM-3 blockade might re-enable anti-leukemic immunity and\/or target TIM-3–positive malignant compartments. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"1494\" data-start=\"1491\"\u003e\n\u003ch2 data-end=\"1531\" data-start=\"1496\"\u003e3) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"1583\" data-start=\"1533\"\u003e3.1 Receptor pharmacodynamics (TIM-3 blockade)\u003c\/h3\u003e\n\u003cp data-end=\"1649\" data-start=\"1584\"\u003ePreclinical characterization supports \u003cstrong data-end=\"1648\" data-start=\"1622\"\u003emulti-pronged activity\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-end=\"2155\" data-start=\"1650\"\u003e\n\u003cli data-end=\"1791\" data-start=\"1650\"\u003e\n\u003cp data-end=\"1791\" data-start=\"1652\"\u003e\u003cstrong data-end=\"1688\" data-start=\"1652\"\u003eBlocks TIM-3–ligand interactions\u003c\/strong\u003e, including \u003cstrong data-end=\"1714\" data-start=\"1700\"\u003egalectin-9\u003c\/strong\u003e and \u003cstrong data-end=\"1750\" data-start=\"1719\"\u003ephosphatidylserine (PtdSer)\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1970\" data-start=\"1792\"\u003e\n\u003cp data-end=\"1970\" data-start=\"1794\"\u003eEnhances immune activation features such as \u003cstrong data-end=\"1889\" data-start=\"1838\"\u003einflammatory cytokine output by dendritic cells\u003c\/strong\u003e and \u003cstrong data-end=\"1912\" data-start=\"1894\"\u003eT-cell killing\u003c\/strong\u003ein model systems. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2155\" data-start=\"1971\"\u003e\n\u003cp data-end=\"2155\" data-start=\"1973\"\u003eFacilitates \u003cstrong data-end=\"2006\" data-start=\"1985\"\u003ephagocytic uptake\u003c\/strong\u003e of TIM-3–expressing target cells (an Fc\/innate-effector–linked mechanism reported in characterization work). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"2213\" data-start=\"2157\"\u003e3.2 “Dual mechanism” concept in myeloid malignancies\u003c\/h3\u003e\n\u003cp data-end=\"2273\" data-start=\"2214\"\u003eMany reviews and trial rationales describe a \u003cstrong data-end=\"2272\" data-start=\"2259\"\u003edual role\u003c\/strong\u003e:\u003c\/p\u003e\n\u003col data-end=\"2504\" data-start=\"2274\"\u003e\n\u003cli data-end=\"2360\" data-start=\"2274\"\u003e\n\u003cp data-end=\"2360\" data-start=\"2277\"\u003e\u003cstrong data-end=\"2298\" data-start=\"2277\"\u003eImmune remodeling\u003c\/strong\u003e (relieving inhibitory TIM-3 signaling on immune cells), and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2504\" data-start=\"2361\"\u003e\n\u003cp data-end=\"2504\" data-start=\"2364\"\u003e\u003cstrong data-end=\"2437\" data-start=\"2364\"\u003eDirect engagement of TIM-3+ malignant cells\/LSC-enriched compartments\u003c\/strong\u003e (disease-context dependent). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-end=\"2509\" data-start=\"2506\"\u003e\n\u003ch2 data-end=\"2560\" data-start=\"2511\"\u003e4) Pharmacokinetics and dosing (program-level)\u003c\/h2\u003e\n\u003cp data-end=\"2838\" data-start=\"2561\"\u003eAs an \u003cstrong data-end=\"2584\" data-start=\"2567\"\u003eIgG4 antibody\u003c\/strong\u003e, sabatolimab shows typical mAb features (limited distribution beyond vascular\/interstitial space; FcRn recycling), and its development included \u003cstrong data-end=\"2770\" data-start=\"2729\"\u003emodel-informed dose\/regimen selection\u003c\/strong\u003e for hematologic malignancies. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"2843\" data-start=\"2840\"\u003e\n\u003ch2 data-end=\"2883\" data-start=\"2845\"\u003e5) Clinical evidence (key datasets)\u003c\/h2\u003e\n\u003ch3 data-end=\"2936\" data-start=\"2885\"\u003e5.1 Phase Ib: sabatolimab + HMA (early signals)\u003c\/h3\u003e\n\u003cp data-end=\"3022\" data-start=\"2937\"\u003eA Phase Ib program combining sabatolimab with \u003cstrong data-end=\"3012\" data-start=\"2983\"\u003eazacitidine or decitabine\u003c\/strong\u003e reported:\u003c\/p\u003e\n\u003cul data-end=\"3244\" data-start=\"3023\"\u003e\n\u003cli data-end=\"3073\" data-start=\"3023\"\u003e\n\u003cp data-end=\"3073\" data-start=\"3025\"\u003e\u003cstrong data-end=\"3066\" data-start=\"3025\"\u003eSafety broadly similar to HMA therapy\u003c\/strong\u003e, and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3244\" data-start=\"3074\"\u003e\n\u003cp data-end=\"3244\" data-start=\"3076\"\u003e\u003cstrong data-end=\"3106\" data-start=\"3076\"\u003edurable clinical responses\u003c\/strong\u003e in higher-risk\/very high-risk MDS cohorts in early-phase evaluation (supporting continued study). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3323\" data-start=\"3246\"\u003e5.2 Randomized Phase II (STIMULUS-MDS1): mixed\/negative primary endpoints\u003c\/h3\u003e\n\u003cp data-end=\"3599\" data-start=\"3324\"\u003eIn a randomized Phase II setting, adding sabatolimab to HMAs \u003cstrong data-end=\"3418\" data-start=\"3385\"\u003edid not significantly improve\u003c\/strong\u003e key endpoints such as \u003cstrong data-end=\"3467\" data-start=\"3441\"\u003ecomplete response rate\u003c\/strong\u003e and \u003cstrong data-end=\"3501\" data-start=\"3472\"\u003eprogression-free survival\u003c\/strong\u003e versus HMA alone, though safety was generally manageable. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"3671\" data-start=\"3601\"\u003e5.3 Phase III (STIMULUS-MDS2): primary results and program outcome\u003c\/h3\u003e\n\u003cp data-end=\"4076\" data-start=\"3672\"\u003ePrimary Phase III readouts presented publicly indicated the combination \u003cstrong data-end=\"3772\" data-start=\"3744\"\u003edid not improve outcomes\u003c\/strong\u003e versus control in the frontline higher-risk MDS setting (per EHA 2024 primary results reporting). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003cbr data-end=\"3913\" data-start=\"3910\"\u003eFollowing these results, reporting in 2024 indicated Novartis \u003cstrong data-end=\"3984\" data-start=\"3975\"\u003eended\u003c\/strong\u003e development in MDS after the pivotal trial outcome. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"4369\" data-start=\"4078\"\u003e\u003cstrong data-end=\"4101\" data-start=\"4078\"\u003eClinical synthesis:\u003c\/strong\u003e Across studies, sabatolimab showed \u003cstrong data-end=\"4189\" data-start=\"4137\"\u003ebiologic plausibility and early activity signals\u003c\/strong\u003e, but \u003cstrong data-end=\"4274\" data-start=\"4195\"\u003erandomized trials did not demonstrate consistent, practice-changing benefit\u003c\/strong\u003e when added to standard HMA therapy in higher-risk MDS. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"4374\" data-start=\"4371\"\u003e\n\u003ch2 data-end=\"4430\" data-start=\"4376\"\u003e6) Safety and tolerability (most defensible points)\u003c\/h2\u003e\n\u003cp data-end=\"4992\" data-start=\"4431\"\u003eAcross accessible trial reporting, sabatolimab + HMA was generally described as having a \u003cstrong data-end=\"4549\" data-start=\"4520\"\u003emanageable safety profile\u003c\/strong\u003e and often similar to HMA-alone expectations, though detailed adverse-event patterns depend on study, dose, and population. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003cbr data-end=\"4715\" data-start=\"4712\"\u003eAs with other checkpoint-style immunotherapies, monitoring focuses on \u003cstrong data-end=\"4815\" data-start=\"4785\"\u003eimmune-mediated toxicities\u003c\/strong\u003e, cytopenias\/infections (in myeloid populations), infusion reactions, and overlapping HMA risks—protocol-defined in the STIMULUS program. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"4997\" data-start=\"4994\"\u003e\n\u003ch2 data-end=\"5075\" data-start=\"4999\"\u003e7) Why efficacy can be hard to realize in MDS (scientific interpretation)\u003c\/h2\u003e\n\u003cp data-end=\"5155\" data-start=\"5076\"\u003eSeveral factors likely constrain TIM-3 blockade performance in higher-risk MDS:\u003c\/p\u003e\n\u003cul data-end=\"5628\" data-start=\"5156\"\u003e\n\u003cli data-end=\"5328\" data-start=\"5156\"\u003e\n\u003cp data-end=\"5328\" data-start=\"5158\"\u003e\u003cstrong data-end=\"5211\" data-start=\"5158\"\u003eComplex immunosuppressive marrow microenvironment\u003c\/strong\u003e with multiple redundant inhibitory axes (TIM-3 may not be dominant alone). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5458\" data-start=\"5329\"\u003e\n\u003cp data-end=\"5458\" data-start=\"5331\"\u003e\u003cstrong data-end=\"5356\" data-start=\"5331\"\u003eDisease heterogeneity\u003c\/strong\u003e (clonal architecture, inflammatory signaling, LSC biology). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5628\" data-start=\"5459\"\u003e\n\u003cp data-end=\"5628\" data-start=\"5461\"\u003e\u003cstrong data-end=\"5505\" data-start=\"5461\"\u003eEndpoint sensitivity and competing risks\u003c\/strong\u003e (infection, cytopenias, rapid progression) that can mask modest immune benefits. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684838273362,"sku":null,"price":5500.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/sabatolimab_10mg.png?v=1770834785","url":"https:\/\/sciencepeptideslab.com\/products\/sabatolimab-mbg453-10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}